Key Takeaways
- • Rev1 Ventures has spun off a dedicated AI and innovation investment vehicle called R1 Capital, led by CEO Tom Walker, based at The Peninsula in Columbus with a mandate spanning AI, enterprise software, deep tech, and life sciences.
- • R1 Capital targets early-stage founders with capital, expertise, and network support to scale from product-market fit to category-defining market leadership, addressing a strategic gap in regional venture funding.
- • Consolidation in venture capital has intensified competitive pressures on regional markets: in 2025, one-third of all venture funding dollars concentrated in the top one percent of companies, creating investment gaps for emerging startups outside major hubs.
- • STAQ Pharma, a Columbus-based life sciences startup founded in 2023 and backed by Rev1 Ventures, exemplifies R1 Capital's thesis—the firm emphasizes operational expertise and mission-aligned advisory support alongside financial models in complex sectors like healthcare.
- • Rev1 Ventures previously generated $718 million in economic impact through portfolio companies and has positioned itself as a Midwest venture studio combining seed-stage capital with startup development services.
Summary
Rev1 Ventures, a Columbus-based startup development and venture capital firm, announced the launch of R1 Capital, a newly independent venture capital firm focused on AI, enterprise software, deep tech, and life sciences investments. Tom Walker, CEO of R1 Capital, stated that the firm was "built to back founders who are reshaping industries through technical innovation," emphasizing support across capital deployment, strategic expertise, and founder networks. The spinoff establishes R1 Capital's headquarters at The Peninsula, where Rev1 opened expanded operations earlier in 2026.
The launch reflects growing concentration risks in venture funding. According to Rev1 leadership, 2025 saw one-third of all venture capital dollars flow to just one percent of companies—a structural shift that has compressed funding availability for smaller markets and earlier-stage ventures outside coastal technology hubs. By establishing a dedicated AI and innovation-focused entity, Rev1 is positioning R1 Capital to address regional funding gaps and support founders at the seed and early-stage transition phases.
The firm's sector focus extends beyond artificial intelligence to encompass deeper technological and operational challenges. Joe Bagan, Co-founder and CEO of STAQ Pharma—a Columbus-based life sciences company founded in 2023 and backed by Rev1 Ventures—highlighted the value of R1 Capital's domain expertise: "When you're building a healthcare company, you need partners who understand both the mission and the complexity behind the work." Bagan noted that operational guidance from advisors with direct experience navigating difficult scaling decisions proved material to STAQ's growth trajectory, underscoring R1 Capital's differentiated value proposition beyond traditional financial modeling.
Rev1 Ventures has established a track record of regional impact: portfolio companies have generated $718 million in cumulative economic impact. The organization operates as a venture studio model, combining seed-stage capital with operational support services. The formation of R1 Capital represents a strategic expansion of this capability, enabling more specialized investment focus while maintaining the parent organization's service infrastructure for founders at earlier development stages.
The launch reflects growing concentration risks in venture funding. According to Rev1 leadership, 2025 saw one-third of all venture capital dollars flow to just one percent of companies—a structural shift that has compressed funding availability for smaller markets and earlier-stage ventures outside coastal technology hubs. By establishing a dedicated AI and innovation-focused entity, Rev1 is positioning R1 Capital to address regional funding gaps and support founders at the seed and early-stage transition phases.
The firm's sector focus extends beyond artificial intelligence to encompass deeper technological and operational challenges. Joe Bagan, Co-founder and CEO of STAQ Pharma—a Columbus-based life sciences company founded in 2023 and backed by Rev1 Ventures—highlighted the value of R1 Capital's domain expertise: "When you're building a healthcare company, you need partners who understand both the mission and the complexity behind the work." Bagan noted that operational guidance from advisors with direct experience navigating difficult scaling decisions proved material to STAQ's growth trajectory, underscoring R1 Capital's differentiated value proposition beyond traditional financial modeling.
Rev1 Ventures has established a track record of regional impact: portfolio companies have generated $718 million in cumulative economic impact. The organization operates as a venture studio model, combining seed-stage capital with operational support services. The formation of R1 Capital represents a strategic expansion of this capability, enabling more specialized investment focus while maintaining the parent organization's service infrastructure for founders at earlier development stages.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.